Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dasatinib 100 mg Clear all
Completed Phase 2 Interventional Results available

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Dasatinib, Dasatinib 100 mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

NCT00779389
View directory record Official record
Conditions
Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions
Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Terminated Phase 1 Interventional

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

NCT01643603
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
Interventions
Dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00550615
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Dasatinib, Dasatinib Maximum Tolerated Dose
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618
View directory record Official record
Conditions
Breast Cancer, Bone Metastases
Interventions
Dasatinib, Zoledronic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

NCT01593254
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Imatinib, Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
21
States / cities
Anaheim, California • Fontana, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Results available

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

NCT01660906
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Anaheim, California • Southington, Connecticut • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

NCT00563290
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Interventions
dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT00982488
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, Imatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
Anaheim, California • Loma Linda, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

NCT00764309
View directory record Official record
Conditions
Scleroderma
Interventions
dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 25, 2026, 1:39 AM EDT
Enrolling by invitation Phase 2 Interventional

Senescence in Chronic Kidney Disease

NCT02848131
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Group 2: Dasatinib, Group 2: Quercetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Study of Erlotinib in Combination With Dasatinib

NCT00895128
View directory record Official record
Conditions
Advanced Cancer
Interventions
Erlotinib Hydrochloride, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 25, 2026, 1:39 AM EDT
Terminated Phase 2 Interventional Results available

Personalized Treatment Selection for Metastatic Breast Cancer

NCT00780676
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib, AZD6244
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

NCT00706641
View directory record Official record
Conditions
Transitional Cell Carcinoma of the Bladder
Interventions
Dasatinib, Radical Cystectomy
Drug · Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

NCT00655746
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib + Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

NCT00371254
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Sep 25, 2026, 1:39 AM EDT
Terminated Early Phase 1 Interventional Results available

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

NCT00835679
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cetuximab, dasatinib, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Tampa, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 25, 2026, 1:39 AM EDT
Terminated Phase 2 Interventional Results available

Dasatinib in Polycythemia Vera

NCT00538980
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Dasatinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • New City, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

NCT04580121
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib, Fulvestrant
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
28
States / cities
Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

NCT00123474
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Alhambra, California • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 25, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

NCT02011945
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 25, 2026, 1:39 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

NCT00817531
View directory record Official record
Conditions
Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 25, 2026, 1:39 AM EDT